NCCN Guidelines® Insights: Ovarian cancer/fallopian tube cancer/primary peritoneal cancer, version 3.2024 Guidelines
| Authors: | Liu, J.; Berchuck, A.; Backes, F. J.; Cohen, J.; Grisham, R.; Leath, C. A. 3rd; Martin, L.; Matei, D.; Miller, D. S.; Robertson, S.; Barroilhet, L.; Uppal, S.; Hendrickson, A. W.; Gershenson, D. M.; Gray, H. J.; Hakam, A.; Jain, A.; Konecny, G. E.; Moroney, J.; Ratner, E.; Schorge, J.; Thaker, P. H.; Werner, T. L.; Zsiros, E.; Behbakht, K.; Chen, L. M.; DeRosa, M.; Eisenhauer, E. L.; Leiserowitz, G.; Litkouhi, B.; McHale, M.; Percac-Lima, S.; Rodabaugh, K.; Vargas, R.; Jones, F.; Kovach, E.; Hang, L.; Ramakrishnan, S.; Alvarez, R. D.; Armstrong, D. K. |
| Title: | NCCN Guidelines® Insights: Ovarian cancer/fallopian tube cancer/primary peritoneal cancer, version 3.2024 |
| Abstract: | The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines. |
| Keywords: | cancer staging; neoplasm staging; ovarian neoplasms; peritoneal neoplasms; practice guideline; pathology; oncology; ovary tumor; diagnosis; medical oncology; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; fallopian tube neoplasms; therapy; peritoneum tumor; procedures; humans; human; female; poly(adp-ribose) polymerase inhibitors; fallopian tube tumor |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 22 |
| Issue: | 8 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2024-10-01 |
| Start Page: | 512 |
| End Page: | 519 |
| Language: | English |
| DOI: | 10.6004/jnccn.2024.0052 |
| PUBMED: | 39413835 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
